Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06564311 · ClinicalTrials.gov registry record · Phase 2

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

A Phase 2 study of Relapsing Multiple Sclerosis, sponsored by Zenas BioPharma (USA).

Active
Registry status
Phase 2
Development phase
93
Enrollment target
20
Study locations

NCT06564311 is a Phase 2 study of Relapsing Multiple Sclerosis that is active but no longer recruiting, run by Zenas BioPharma (USA). The registered enrollment target is 93 participants, below the 2,165-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06564311, a Phase 2 study of Relapsing Multiple Sclerosis, is active but no longer recruiting, sponsored by Zenas BioPharma (USA).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
93 participants
Enrollment target
20
Study locations

Study Summary

This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis

Conditions Studied

Relapsing Multiple Sclerosis

Interventions

  • DRUG Placebo
  • DRUG Obexelimab

Study Locations (20)

Other

  • Neuro-logisch Wien - Vienna
  • Rehabilitation & MS Center, Noorderhart Hospital - Overpelt
  • AZ Delta-Deltalaan 1 - Roeselare
  • Tiantan Hospital, Capital Medical University - Beijing
  • The First Affiliation Hospital of Soochow University - Suzhou
  • Tianjin Medical University General Hospital - Tianjin

Arizona

  • Center for Neurology and Spine - Phoenix
  • Perseverance Research Center - Scottsdale

Florida

  • Aqualine Clinical Research - Naples
  • University of South Florida - Tampa

Wisconsin

  • Center for Neurological Disorders - Greenfield
  • Medical College of Wisconsin - Milwaukee

Alabama

  • North Central Neurology - Cullman

California

  • Regina Berkovich MD PhD, Inc - West Hollywood

Massachusetts

  • University of Massachusetts Medical School - Worcester

Minnesota

  • Infusion Associates Plymouth - Plymouth

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2024-08-26
Est. Completion 2026-02
Phase Phase 2

Sponsor

Zenas BioPharma (USA)

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06564311

The ClinicalTrials.gov registry entry for NCT06564311 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,165-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (96% lower). The listed sponsor is Zenas BioPharma (USA), which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06564311 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT06564311 about?

NCT06564311 is a clinical study titled "A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)". This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis

What is the current status of trial NCT06564311?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2024-08-26. Estimated completion is 2026-02.

What conditions does trial NCT06564311 study?

This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.

What interventions are being tested in trial NCT06564311?

The interventions under investigation include: Placebo (DRUG), Obexelimab (DRUG).

Who is sponsoring clinical trial NCT06564311?

This trial is sponsored by Zenas BioPharma (USA), which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06564311 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsing Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsing Multiple Sclerosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.